Scott Bizily, 4D Molecular Therapeutics CLO, sells $20,993 in stock

Scott Bizily, the Chief Legal Officer at 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), divested shares of the company's common stock worth $20,993 on October 16, 2026. Bizily sold 1,635 shares at a price of $12.84 each, while simultaneously purchasing 1,635 shares for a total cost of $6,768 at a rate of $4.14 per share. Both the sale and acquisition were carried out under a pre-arranged 10b5-1 trading plan that Bizily established on January 13, 2026.

Post these transactions, Bizily now owns 8,617 shares of 4D Molecular Therapeutics common stock, in addition to 56,431 stock options. Currently, the company's stock price is $13.10, marking a 74.67% increase year-to-date. However, InvestingPro analysis indicates that the company may still be undervalued compared to its Fair Value.

The stock has a beta of 2.74, signifying high volatility. 4D Molecular Therapeutics has garnered attention from various analysts and has seen updates regarding its trials. BofA Securities raised its price target to $33 and maintained a Buy rating, citing positive results from the SPECTRA and 4SIGHT trials. Cantor Fitzgerald upgraded the stock to Overweight from Neutral, expressing optimism about the gene therapy potential of 4D-150.

B.Riley reiterated a Buy rating with a $37 price target, emphasizing the trial design of the 4FRONT Phase 3 studies. H.C. Wainwright also reaffirmed its Buy rating with a $36 target, acknowledging the successful Phase 3 trials involving both treatment-naïve and previously treated patients. These developments highlight the company's promising trial data and future prospects. This report was AI-generated and reviewed by an editor.